# Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

> **NCT05236036** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 60 (estimated)

## Conditions studied

- Astrocytoma
- Glioblastoma
- Glioblastoma, IDH-Wildtype
- MGMT-Unmethylated Glioblastoma
- Recurrent Glioblastoma

## Interventions

- **DRUG:** Mycophenolate Mofetil
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05236036
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-08
- **Primary completion:** 2026-01-12
- **Final completion:** 2029-01-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05236036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05236036, "Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05236036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*